Press Release: Inspire Pharmaceuticals Announces FDA Approval Of AzaSite - FierceBiotech

Press Release: Inspire Pharmaceuticals Announces FDA Approval Of AzaSite - FierceBiotech: "DURHAM, N.C. -- Inspire Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved AzaSite(TM) (azithromycin ophthalmic solution) 1% for the treatment of bacterial conjunctivitis. Inspire anticipates launching AzaSite in the latter part of the third quarter of 2007 and expects to generate $30 - $45 million in sales in the 2008 calendar year based on current manufacturing and commercial plans."